Skip to main content
OpenTrials
Completed

NCT Number: NCT00996489

This is a Post Approval Study of Coaptite® in the Treatment of Female Urinary Incontinence

This is a post approval study of Coaptite® in the treatment of female urinary incontinence.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Wetumpka, Alabama, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Has female stress urinary incontinence that is due to intrinsic sphincter deficiency
  • Has a baseline pad weight of greater than or equal to 50 grams
  • Has viable mucosal lining at likely site of injection (bladder neck)
  • Is at least 18 years of age
  • Understands and accepts the obligation and is logistically able to present for all scheduled study visits
  • Signs written informed consent

Exclusion criteria

  • Has had a previous treatment for urinary incontinence with a urethral bulking agent other than Coaptite® or collagen
  • Has detrusor instability
  • Has bladder neuropathy
  • Has nocturnal enuresis (bed wetting)
  • Has Grade II or III prolapsed bladder
  • Has overflow or functional incontinence
  • Has significant history of urinary tract infections without resolution
  • Has current or acute conditions of cystitis or urethritis
  • Has history of significant pelvic irradiation
  • Is pregnant or lactating

Treatment and study plan

Coaptite®

Device

Calcium hydroxylapatite particles suspended in an aqueous based gel carrier

Primary outcomes

  1. Incontinence Status as Assessed by Stamey Grade Score

    Time frame: Baseline and Months 6, 12, 18, 24, 30, and 36

    The Stamey grade classifies the severity stress incontinence and was calculated from the 4-day voiding diary using the four possible grades from 0-3. Grade 0: controlled urination, Grade 1: accidents with vigorous activity, for example, lifting weights, coughing, and sneezing, Grade 2: accidents with minimal activity, for example, walking and standing up, and Grade 3: accidents regardless of activity or position and that cannot be attributed to a specific activity. Higher the Stamey grade, the most severe leakage level was estimated. An average of 4 days for the final grade was recorded and rounded up, if necessary (for example, 2.5 was equal to Grade 3).

  2. Number of Participants With One Point Improvement in Stamey Grade Scores up to Month 12

    Time frame: Baseline up to Month 12

    The Stamey grade classifies the severity stress incontinence and was calculated from the 4-day voiding diary using the four possible grades from 0-3. Grade 0: controlled urination, Grade 1: accidents with vigorous activity, for example, lifting weights, coughing, and sneezing, Grade 2: accidents with minimal activity, for example, walking and standing up, and Grade 3: accidents regardless of activity or position and that cannot be attributed to a specific activity. Higher the Stamey grade, the most severe leakage level was estimated. An average of 4 days for the final grade was recorded and rounded up, if necessary (for example, 2.5 was equal to Grade 3).

  3. Number of Participants Who Had at Least One Point Improvement in Stamey Grade Scores Compared to Baseline

    Time frame: Months 6, 12, 18, 24, 30, and 36

    The Stamey grade classifies the severity stress incontinence and was calculated from the 4-day voiding diary using the four possible grades from 0-3. Grade 0: controlled urination, Grade 1: accidents with vigorous activity, for example, lifting weights, coughing, and sneezing, Grade 2: accidents with minimal activity, for example, walking and standing up, and Grade 3: accidents regardless of activity or position and that cannot be attributed to a specific activity. Higher the Stamey grade, the most severe leakage level was estimated. An average of 4 days for the final grade was recorded and rounded up, if necessary (for example, 2.5 was equal to Grade 3).

  4. Number of Participants With Change From Baseline in Stamey Grade Scores Over Time

    Time frame: Baseline up to Months 6 and 12

    The Stamey grade classifies the severity stress incontinence and was calculated from the 4-day voiding diary using the four possible grades from 0-3. Grade 0: controlled urination, Grade 1: accidents with vigorous activity, for example, lifting weights, coughing, and sneezing, Grade 2: accidents with minimal activity, for example, walking and standing up, and Grade 3: accidents regardless of activity or position and that cannot be attributed to a specific activity. Higher the Stamey grade, the most severe leakage level was estimated. An average of 4 days for the final grade was recorded and rounded up, if necessary (for example, 2.5 was equal to Grade 3).

  5. Number of Participants Who Experience at Least One Treatment Emergent Adverse Event (TEAE)

    Time frame: Baseline up to Month 36

Secondary outcomes

  1. Number of Participants Who Received Each of the Six Coaptite Injections

    Time frame: Baseline up to Month 36

    Coaptite injection were given to any participant during the 36 months of evaluation.

  2. Time to Coaptite Retreatment

    Time frame: Baseline up to Month 36

    Time to additional coaptite treatment or any other alternative treatment for stress urinary incontinence was recorded to assess the durability of effect.

  3. Number of Participants With Alternative Treatments for Incontinence

    Time frame: Baseline up to Month 6 and Months 6 to 12, 12 to 18, 18 to 24, 24 to 30, 30 to 36

    Number of participants with alternative treatment such as kegel exercises, sling, sling/cystocele repair, surgery, permanent abdominal tube, intravesical botox, sling/graft, sling removal, estradiol vaginal cream, bladder neck suspension, tension free vaginal tape, biofeedback, polydimethylsiloxane injections, solifenacin orally, bladder specific control physical therapy, for stress urinary incontinence were assessed.

  4. Number of Participants With Urge Incontinence Medication (UIM) Status

    Time frame: Baseline up to Month 36

    The use of urge incontinence medications was collected pre-treatment and post-treatment.

  5. Incontinence Quality of Life (iQoL) Scores

    Time frame: Baseline and Months 6, 12, 18, 24, 30, and 36

    The iQoL measured the effect of urinary incontinence on QoL. It was divided into 3 subscales: 1 (avoidance and limiting behaviour); 2 (psychosocial impact), and 3 (social embarrassment). The iQOL was comprised of 22 items, each with the response scale from 1 (extremely) to 5 (not at all). A mean score for each subscale was calculated (averaging the scores for the items in each subscale) as well as a total score for all 22 items (sum of all subscale scores). The scores were then transformed to a scale score ranging from 0 to 100 points, where higher scores indicated less impact of incontinence on QoL.

  6. Volume of Coaptite Injected Per Treatment

    Time frame: Baseline, Baseline to Month 6 and Months 6 to 12, 12 to 18, 18 to 24, 24 to 30, 30 to 36

  7. Mean Number of Sites Injected by Coaptite

    Time frame: Baseline, Baseline to Month 6 and Months 6 to 12, 12 to 18, 18 to 24, 24 to 30, 30 to 36

Sponsors and collaborators

Lead sponsor

Merz North America, Inc.

Industry

Registry information

Official study title

Post-approval of Coaptite® in the Treatment of Female Urinary Incontinence

Important dates

Study start
2008
Primary completion
2015
Study completion
2015
First posted
Oct 16, 2009
Registry last updated
Jul 23, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.